English
The MiRAVALVE-CKD translational proposal aims to provide preclinical and clinical data to support a beneficial impact of Mineralocorticoid Receptor (MR) antagonism (MRA)/Neutrophil Gelatinase Associated Lipocalin (NGAL) /Galectin3 (Gal-3) pathways in Chronic kidney Disease (CKD)-associated aortic valve (AV) calcification. RESEARCH HYPOTHESIS: MR, NGAL and/or Gal-3 are crucial for reduction of AV calcification associated with CKD by modulating ECM remodeling and inflammation OBJECTIVES OF THE PROPOSAL are to investigate: 1) the impact of MRAs on AV calcification associated to CKD; 2) the role of NGAL and Gal-3, both MR targets involved in cardiorenal diseases and inflammation, in a context of CKD; 3) the gender impact on valvular MR signaling ; 4) the clinical relevance of these preclinical data, by assessing biomarkers in available AS patients cohorts and in primary valvular cultured cells from AS patients with or without CKD. The project, with a duration of 42 months, is organized around 4 interacting work packages (WP): WP1: does MRA limit AV calcification associated with CKD? By which mechanisms? WP2: what is the role of the MR targets, NGAL and Gal3 in CKD- associated AV calcification? i WP3: impact of sex? WP 4: MRA-modulated biomarkers in patients with aortic stenosis. Impact of CKD and gender MiRAVALVE-CKD builds a consortium of excellence bridging key opinion leaders in the field of mineralocorticoids (both in experimental science and clinical trials), with outstanding experts in the field of small animal CV phenotyping or access to human AV samples for biomarker analysis and primary valvular cell culture. All partners already generated data related to the project that strengthen the hypothesis. Each partner has specific expertise (pathophysiological approaches, drug testing, clinical research) which is of added value to the project, fostering an ambitious and innovative but realistic
